4th Annual Bradley Z. Naifeh Amyloidosis Conference - Medical Professional Conference - May 9, 2026 - FREE (NO CE CREDIT)
THIS REGISTRATION OPTION IS AVAILABLE ONLY FOR PRIVATE PHYSICIANS LOCATED WITHIN THE GREATER HOUSTON AREA.
CE CREDIT IS NOT AVAILABLE FOR THE FREE SESSION. PRIVATE PHYSICIANS WISHING TO RECEIVE CE CREDIT MUST REGISTER FOR AND PAY THE FAIR MARKET VALUE RATE FOR THE CE CREDIT OFFERING OF THIS ACTIVITY.
Virtual attendance option only
Houston Methodist J.C. Walter Educational Series
Amyloidosis is an underrecognized condition because it has historically been misconceived to be a rare disease and presents in a myriad of clinical situations in a subtle manner. Recent advances in therapeutics have made it imperative that this condition is recognized and categorized appropriately in a timely manner so that individuals can get access to appropriate care. Due to a systemic nature of amyloid, various subspecialities are on the fore front of battling this disease. The goal of the Conference is to create a faculty panel from various disciplines to engage in the mission to promote awareness and educate attendees on Amyloidosis in a comprehensive manner.
Target Audience
Cardiologists, hematologists, neurologists, nephrologists, pulmonologists, hepatologists, nurse practitioners, nurses, social workers, transplant coordinators, and trainees in these subspecialities.
Learning Objectives
Upon completion of this course, the participant should be able to:
- Identify and Diagnose Amyloidosis Early & Effectively
- Apply Best Practices to Treat Amyloidosis
- Utilize Appropriate Resources Available to Providers and Patients alike (non-profit institutions)
- Describe the full influence of Amyloidosis: how it affects multiple specialties and all parts of the body, and how it becomes a fatal disease
- List the multiple types of Amyloidosis
| H O U S T O N M E T H O D I S T J . C . W A L T E R J R C O N F E R E N C E S E R I E S | ||
| 4th Annual Bradley Z. Naifeh Amyloidosis Conference Medical Professionals Day Saturday, May 9, 2026 | Hybrid Symposium | ||
| TIME | PRESENTATION | SPEAKER(S) |
| 7:00 AM | Registration & Breakfast | |
| 8:00 AM | Executive Welcome Overview of Amyloidosis mission at Houston Methodist | R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed) |
| 8:05 AM | Introduction of the Bradley Z. Naifeh Amyloidosis Program | Arvind Bhimaraj, MD, MPH, FACC, FHFSA |
| 8:10 AM | A message from the Naifeh Family | Valerie Naifeh |
| 8:20 AM | Types of Amylodisois and the Numbers: Why We Care? | Barry Trachtenberg, MD |
| PLENARY SESSION I: TTR Amyloidosis: A Fast Advancing Field Moderators: Mahwash Kassi, MD; Arvind Bhimaraj, MD Panelist: | ||
| 8:30 AM | Stage A to Stage D Cardiac Amyloidosis : A Paradigm to match the current landscape | Arvind Bhimaraj, MD, MPH, FACC, FHFSA |
| 9:00 AM | Understanding Pathobiology of TTR Amyloidosis | Lorena Saelices Gomez, Ph.D. |
| 9:25 AM | Orthopedics as a crucial speciality to beat ATTR at a population level | Dr. Shari Liberman |
| 9:35 AM | The Neurotrophic Manifestations of ATTR Amyloidosis | Dr. Sheetal Shroff |
| 9:45 AM | Q&A and Panel Discussion | |
| 9:55 AM | Break | |
| PLENARY SESSION II: AL Amyloidosis: The Disease We Cannot Ignore Moderators: Hematology, Mouz Al-Malah Panelist: Mouz Al-Malah; Dipan Shah | ||
| 10:10 AM | AL Amyloidosis as a spectrum of plasma cell dyscarias or a uniquely seprate entity | Dr. Raymond Comenzo |
| 10:40 AM | Imaging the Heart, Hope or Hype: Diagnostic ablity to distinguish subtypes and follow therapeutic reponse | Dr. Sarah Cuddy |
| 10:50 AM | Kidneys as the cornerstone of AL amyloidosis: Why nephrologists need to be Amyloid doctors | Horacio Adrogue, MD |
| 11:00 AM | Q&A and Panel Discussion | |
| PLENARY SESSION III: Patient Perspective and Support Groups: How to Support our Patients Moderators: Arvind Bhimaraj, MD; Barry Trachtenberg, MD Panelist: | ||
| 11:10 AM | Pathways to Connect: Support Groups for Amyloidosis Patients | Patient Support Groups: Amyloidosis Speakers Bureau (ASB) Amyloidosis Research Consortium (ARC) Amyloidosis Support Groups (ASG) Benjamin Lavine Somebody To Talk To |
| 11:20 AM | ||
| 11:40 AM | Q&A and Panel Discussion | |
| 11:50 PM | Lunch | |
| 11:50 PM | PRODUCT THEATRE (Presented in Boardroom) *Not certified for CE credit* | |
| PLENARY SESSION IV: Treatment Options for Amyloidosis Moderators: Arvind Bhimaraj, MD; Barry Trachtenberg, MD Panelist: | ||
| 1:20 PM | ATTR treatment options: Current and Future | Dr. Mahwash Kassi |
| 1:45 PM | AL Amyloidosis Updates in Treatment | Hematology |
| 2:00 PM | DEBATE: KNOCK IT DOWN: TTR IS NOT A CRITICAL PROTEIN FOR HUMAN HOMEOSTASIS (PR0) | Dr. Sarah Cuddy |
| 2:15 PM | DEBATE: KNOCK IT DOWN: TTR IS NOT A CRITICAL PROTEIN FOR HUMAN HOMEOSTASIS (CON) | Lorena Saelices Gomez, Ph.D. |
| 2:30 PM | REBUTTAL: 3 min each | |
| 2:50 PM | Q&A and Panel Discussion | |
| 3:00 PM | Concluding Remarks | |
| 3:10 PM | Adjourn | |

Virtual
Available Credit
- 5.00 Attendance

Facebook
X
LinkedIn
Forward